By Linsey Battan
Dr. Guang-Shing Cheng has joined the Hutchinson Center's Clinical Research Division faculty. Her research focuses on improving outcomes for stem cell transplant patients with respiratory failure and on advancing diagnostic strategies for early detection of lung infections and cancer.
In addition to providing inpatient services for critically ill patients, Cheng diagnoses and manages respiratory illnesses in Seattle Cancer Care Alliance patients, a population with a lot of unusual respiratory infections, as well as toxicity to chemotherapies. She also performs bronchoscopies for the diagnosis of respiratory infections, early detection of lung cancer, and other pulmonary conditions.
She studied at Harvard University as an undergraduate and pursued her medical degree at the University of California at San Francisco. Cheng did her medical residency and pulmonary/critical care fellowship at Yale-New Haven Hospital.
Cheng, who joined the Center earlier this year, said she came here to be part of a team effort that helps people through the process of their life-changing transplant experience, as well as through their journey with cancer. "Here I have an opportunity to practice very sub-specialized medicine with world-class individuals who are not only engaged in cutting-edge research, but also the very best clinical medicine.
"This is an opportunity for me to gain a specific expertise within pulmonary medicine, as well as to engage in research that will have a positive impact on patient care," said Cheng, who is also an assistant professor with the University of Washington's Pulmonary, Critical Care and Sleep Medicine division.
"I am very excited to have Guang-Shing join our pulmonary and critical care medicine program," said Dr. David Madtes, a pulmonary researcher in the Clinical Research Division and director of SCCA's Lung Cancer Early Detection and Prevention Clinic.
"She is a bright young clinician-scholar with a passion for teaching and clinical research. Her special interests in respiratory failure after hematopoietic stem cell transplantation and minimally invasive methods to diagnose and stage lung cancer are highly valuable to the Center's mission."